GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Capex-to-Operating-Cash-Flow

Waverley Pharma (TSXV:WAVE) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Waverley Pharma's Capital Expenditure for the three months ended in Mar. 2024 was C$0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was C$-0.11 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Waverley Pharma Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Waverley Pharma's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Capex-to-Operating-Cash-Flow Chart

Waverley Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Waverley Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Waverley Pharma's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Waverley Pharma's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waverley Pharma's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's Capex-to-Operating-Cash-Flow falls into.



Waverley Pharma Capex-to-Operating-Cash-Flow Calculation

Waverley Pharma's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -1.021
=N/A

Waverley Pharma's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.112
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Waverley Pharma  (TSXV:WAVE) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Waverley Pharma Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Waverley Pharma (TSXV:WAVE) Business Description

Traded in Other Exchanges
Address
1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Executives
Albert David Friesen 10% Security Holder, Director, Senior Officer

Waverley Pharma (TSXV:WAVE) Headlines

From GuruFocus

California Senate Approves Wave and Tidal Renewable Energy Bill

By PRNewswire PRNewswire 06-20-2023

Eco Wave Power Global AB (publ) Published Annual Report 2022

By PRNewswire PRNewswire 06-07-2023